Pacira BioSciences, Net Worth
Pacira BioSciences, Net Worth Breakdown | PCRX |
Pacira BioSciences, Net Worth Analysis
Pacira BioSciences,'s net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Pacira BioSciences,'s financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Pacira BioSciences,'s overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Pacira BioSciences,'s net worth analysis. One common approach is to calculate Pacira BioSciences,'s market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Pacira BioSciences,'s stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Pacira BioSciences,'s net worth. This approach calculates the present value of Pacira BioSciences,'s future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Pacira BioSciences,'s cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Pacira BioSciences,'s net worth. This involves comparing Pacira BioSciences,'s financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Pacira BioSciences,'s net worth relative to its peers.
Enterprise Value |
|
To determine if Pacira BioSciences, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pacira BioSciences,'s net worth research are outlined below:
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Why Pacira is a Top Momentum Stock for the Long-Term |
Pacira BioSciences, uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Pacira BioSciences,. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pacira BioSciences,'s previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Pacira BioSciences,'s Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pacira BioSciences, is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pacira BioSciences, backward and forwards among themselves. Pacira BioSciences,'s institutional investor refers to the entity that pools money to purchase Pacira BioSciences,'s securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Marshall Wace Asset Management Ltd | 2024-06-30 | 971.1 K | Rock Springs Capital Management Lp | 2024-06-30 | 785 K | Nuveen Asset Management, Llc | 2024-06-30 | 711.2 K | Hhg Plc | 2024-06-30 | 698.4 K | Schroder Investment Management Group | 2024-06-30 | 616.8 K | Jpmorgan Chase & Co | 2024-06-30 | 600.6 K | Bank Of America Corp | 2024-06-30 | 559 K | Cubist Systematic Strategies, Llc | 2024-09-30 | 554.4 K | Assenagon Asset Management Sa | 2024-09-30 | 553.1 K | Blackrock Inc | 2024-06-30 | 8 M | Vanguard Group Inc | 2024-09-30 | 5.3 M |
Follow Pacira BioSciences,'s market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 780.79 M.Market Cap |
|
Project Pacira BioSciences,'s profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.05 | 0.05 | |
| Return On Capital Employed | 0.06 | 0.06 | |
| Return On Assets | 0.03 | 0.03 | |
| Return On Equity | 0.05 | 0.05 |
When accessing Pacira BioSciences,'s net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Pacira BioSciences,'s profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pacira BioSciences,'s profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Pacira BioSciences,'s accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pacira BioSciences,. Check Pacira BioSciences,'s Beneish M Score to see the likelihood of Pacira BioSciences,'s management manipulating its earnings.
Evaluate Pacira BioSciences,'s management efficiency
Pacira BioSciences, has return on total asset (ROA) of 0.0417 % which means that it generated a profit of $0.0417 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1148) %, meaning that it created substantial loss on money invested by shareholders. Pacira BioSciences,'s management efficiency ratios could be used to measure how well Pacira BioSciences, manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.05 in 2024. Return On Capital Employed is likely to rise to 0.06 in 2024. At this time, Pacira BioSciences,'s Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 1.1 B in 2024, whereas Other Assets are likely to drop 0.95 in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 18.83 | 19.77 | |
| Tangible Book Value Per Share | 4.84 | 5.08 | |
| Enterprise Value Over EBITDA | 12.64 | 12.01 | |
| Price Book Value Ratio | 1.79 | 1.70 | |
| Enterprise Value Multiple | 12.64 | 12.01 | |
| Price Fair Value | 1.79 | 1.70 | |
| Enterprise Value | 1.7 B | 1.8 B |
The strategic initiatives led by Pacira BioSciences,'s management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 1.3978 | Revenue 695 M | Quarterly Revenue Growth 0.028 | Revenue Per Share 15.006 | Return On Equity (0.11) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pacira BioSciences, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pacira BioSciences,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pacira BioSciences, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pacira BioSciences, Corporate Filings
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 5th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 23rd of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 13th of August 2024 Other Reports | ViewVerify |
Pacira BioSciences, Earnings per Share Projection vs Actual
Pacira BioSciences, Corporate Management
| Richard Kahr | Vice Resources | Profile | |
| Daryl Gaugler | Chief Officer | Profile | |
| Charles Laranjeira | Chief Technical Officer | Profile | |
| Christopher Young | Chief Officer | Profile | |
| Shawn Cross | Chief Officer | Profile | |
| DO Ellis | Chief Officer | Profile | |
| III CPA | Chief Officer | Profile |
Additional Tools for Pacira Stock Analysis
When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.